GlassScriptPhysician profile
Min S Kang
NPI 1457358749
$6,099.85
in general payments reported to CMS, 2019-2025
23 companies · $483 in 2025
The $483 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,671 · 2020: $195 · 2021: $1,665 · 2022: $552 · 2023: $340 · 2024: $193 · 2025: $483.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $850 · Long Term Medical Supply Or Device Loan: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $850.01 |
| Long Term Medical Supply Or Device Loan | $166.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $2,269.81 | 2019-2025 | Opdivo |
| Novartis Pharmaceuticals Corporation | $1,233.59 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,048.88 | 2019-2021 | |
| Abbvie INC. | $337.69 | 2023-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $219.36 | 2021-2023 | Imbruvica |
| Astrazeneca Pharmaceuticals LP | $219.08 | 2019-2025 | Calquence |
| Astellas Pharma US INC | $180.90 | 2020-2025 | Vyloy |
| Seagen INC. | $95.00 | 2020 | |
| Beone Medicines USA, INC. | $50.56 | 2025 | Tevimbra |
| Glaxosmithkline, LLC. | $50.41 | 2023-2025 | Ojjaara, Blenrep |
| Amgen INC. | $48.45 | 2019-2021 | |
| Eisai INC. | $45.58 | 2022-2025 | |
| Genzyme Corporation | $38.96 | 2019-2021 | |
| Pfizer INC. | $36.05 | 2019-2025 | |
| Janssen Biotech, INC. | $33.74 | 2025 | Carvykti |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $30.11 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $30.03 | 2022 | |
| Tersera Therapeutics LLC | $28.93 | 2021 | |
| Dendreon Pharmaceuticals LLC | $28.69 | 2024 | Provenge |
| Acorda Therapeutics, INC | $21.84 | 2023 | Ampyra, Inbrija |
| Roche Diagnostics Corporation | $20.88 | 2019 | |
| Sumitomo Pharma America, INC. | $16.06 | 2024 | Orgovyx |
| Beigene USA, INC. | $15.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Min Kang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.